Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lone Skov

Showing results (21-30 of 362) with videos related to

Pageof 37
Sort By:
Journal of the American Academy of Dermatology|June 7, 2019
Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'"Alexander Egeberg, Lars Erik Bryld, Lone Skov
Ugeskrift for Laeger|February 3, 2018
[Atopic dermatitis]Trine Gerner, Lone Skov, Jacob Pontoppidan Thyssen
Expert Review of Clinical Immunology|April 14, 2020
Cancer risk in patients with psoriasis: should we be paying more attention?Nikolai Dyrberg Loft, Sofie Vaengebjerg, Lone Skov
Immunotherapy|November 17, 2015
Targeting IL-17 with ixekizumab in patients with psoriasisBeatrice Dyring-Andersen, Lone Skov, Claus Zachariae
Expert Review of Clinical Immunology|March 10, 2015
Ixekizumab for treatment of psoriasisBeatrice Dyring-Andersen, Lone Skov, Claus Zachariae
Experimental Dermatology|March 13, 2003
Biological response modifiers and their potential use in the treatment of inflammatory skin diseasesLouise S Villadsen, Lone Skov, Ole Baadsgaard
Ugeskrift for Laeger|October 9, 2014
[Obstetric dermatoses]Sofie Hjortø, Lone Skov, Jacob Alexander Lykke
Ugeskrift for Laeger|April 2, 2025
[Vitiligo]Morten Bahrt Haulrig, Luise Idorn, Lone Skov
Therapeutics and Clinical Risk Management|October 16, 2020
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque PsoriasisCharlotte Näslund-Koch, Claus Zachariae, Lone Skov
Journal of the American Academy of Dermatology|November 6, 2017
Cause-specific mortality in adults with atopic dermatitisJacob P Thyssen, Lone Skov, Alexander Egeberg
Pageof 37

Showing results (21-30 of 362) with videos related to

Sort By:
Pageof 37
Journal of the American Academy of Dermatology|June 7, 2019
Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'"Alexander Egeberg, Lars Erik Bryld, Lone Skov
Ugeskrift for Laeger|February 3, 2018
[Atopic dermatitis]Trine Gerner, Lone Skov, Jacob Pontoppidan Thyssen
Expert Review of Clinical Immunology|April 14, 2020
Cancer risk in patients with psoriasis: should we be paying more attention?Nikolai Dyrberg Loft, Sofie Vaengebjerg, Lone Skov
Immunotherapy|November 17, 2015
Targeting IL-17 with ixekizumab in patients with psoriasisBeatrice Dyring-Andersen, Lone Skov, Claus Zachariae
Expert Review of Clinical Immunology|March 10, 2015
Ixekizumab for treatment of psoriasisBeatrice Dyring-Andersen, Lone Skov, Claus Zachariae
Experimental Dermatology|March 13, 2003
Biological response modifiers and their potential use in the treatment of inflammatory skin diseasesLouise S Villadsen, Lone Skov, Ole Baadsgaard
Ugeskrift for Laeger|October 9, 2014
[Obstetric dermatoses]Sofie Hjortø, Lone Skov, Jacob Alexander Lykke
Ugeskrift for Laeger|April 2, 2025
[Vitiligo]Morten Bahrt Haulrig, Luise Idorn, Lone Skov
Therapeutics and Clinical Risk Management|October 16, 2020
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque PsoriasisCharlotte Näslund-Koch, Claus Zachariae, Lone Skov
Journal of the American Academy of Dermatology|November 6, 2017
Cause-specific mortality in adults with atopic dermatitisJacob P Thyssen, Lone Skov, Alexander Egeberg
Pageof 37